down arrow

Frontier Biotechnologies, Inc. (China)

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100005XF5
  • SHG: 688221
CNY
16.73
-0.75 (-4.29%)

Sep 24

SHG

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Frontier Biotechnologies, Inc. (China)

Why is Frontier Biotechnologies, Inc. (China) ?

1
The company is Net-Debt Free
  • Poor long term growth as Net Sales has grown by an annual rate of 50.61% and Operating profit at 14.29% over the last 5 years
  • The company is Net-Debt Free
2
Poor long term growth as Net Sales has grown by an annual rate of 50.61% and Operating profit at 14.29% over the last 5 years
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 10.85%, its profits have risen by 102% ; the PEG ratio of the company is 19.1
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Frontier Biotechnologies, Inc. (China) for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Frontier Biotechnologies, Inc. (China)
10.07%
2.68
77.21%
China Shanghai Composite
0.9%
0.22
14.72%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
50.61%
EBIT Growth (5y)
14.29%
EBIT to Interest (avg)
-45.76
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.10
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
1945
Industry P/E
Price to Book Value
6.63
EV to EBIT
-571.83
EV to EBITDA
339.72
EV to Capital Employed
8.34
EV to Sales
18.08
PEG Ratio
19.07
Dividend Yield
NA
ROCE (Latest)
-1.46%
ROE (Latest)
0.34%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

27What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY 64.53 MM

NET SALES(HY)

Higher at CNY 313.3 MM

NET PROFIT(HY)

Higher at CNY 144.72 MM

ROCE(HY)

Highest at -2.1%

DEBT-EQUITY RATIO (HY)

Lowest at -47.13 %

-12What is not working for the Company
PRE-TAX PROFIT(Q)

At CNY -83.25 MM has Fallen at -56.66%

NET PROFIT(Q)

At CNY -82.65 MM has Fallen at -55.53%

RAW MATERIAL COST(Y)

Grown by 671.99% (YoY

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.64 times

NET SALES(Q)

Lowest at CNY 16.16 MM

Here's what is working for Frontier Biotechnologies, Inc. (China)

Operating Cash Flow
Highest at CNY 64.53 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Debt-Equity Ratio
Lowest at -47.13 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Frontier Biotechnologies, Inc. (China)

Net Sales
At CNY 16.16 MM has Fallen at -46.67%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely negative

Net Sales (CNY MM)

Pre-Tax Profit
At CNY -83.25 MM has Fallen at -56.66%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Profit
At CNY -82.65 MM has Fallen at -55.53%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (CNY MM)

Net Sales
Lowest at CNY 16.16 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (CNY MM)

Inventory Turnover Ratio
Lowest at 1.64 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Raw Material Cost
Grown by 671.99% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Footer loading